INDIANAPOLIS, June 11, 2015 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) will host a webcast on June 23 to discuss three pivotal Phase III
studies investigating ixekizumab for the treatment of
moderate-to-severe plaque psoriasis. Data from the UNCOVER-1, -2
and -3 clinical studies will be discussed. In March, data from
UNCOVER-1 was presented at the American Academy of Dermatology
annual meeting. Earlier this month, additional data from UNCOVER-1
as well as data from UNCOVER-2 and -3 were presented at the World
Congress of Dermatology.
The webcast will begin at 10:00 a.m.
Eastern Daylight Time. A live audio webcast will be
available on the "Webcasts & Presentations" section of Lilly's
investor website at http://investor.lilly.com/events.cfm. A replay
will be available for approximately one week.
About Ixekizumab
Ixekizumab is a monoclonal antibody
with high affinity and specificity that binds to and neutralizes
the pro-inflammatory cytokine interleukin-17A (IL-17A). In
psoriasis, IL-17A plays a major role in driving excess keratinocyte
(skin cell) proliferation and activation. Ixekizumab does not bind
to cytokines IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. Ixekizumab
is administered via subcutaneous injection (under the skin).
Ixekizumab is also in clinical development for the treatment of
psoriatic arthritis.
About Ixekizumab UNCOVER Phase III Trials
The UNCOVER
studies are double-blind, multicenter, Phase III studies evaluating
more than 3,800 patients with moderate-to-severe psoriasis in 18
countries. UNCOVER-1 compared the safety and efficacy of different
dosing regimens of ixekizumab with placebo after 12 weeks and 60
weeks of treatment. The UNCOVER-2 and -3 studies assigned patients
to receive either placebo, etanercept (50 mg twice a week) or
ixekizumab (80 mg every two or four weeks) for 12 weeks, following
a 160 mg starting dose.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
http://newsroom.lilly.com/social-channels.
P-LLY
Refer to:
Tim Coulom; tim.coulom@lilly.com;
(317) 771-2241 (Media)
Lauren Zierke;
lauren_zierke@lilly.com; (317) 277-6524 (Media)
Phil Johnson;
johnson_philip_l@lilly.com; (317) 655-6874 (Investors)
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-discuss-ixekizumab-phase-iii-data-300097859.html
SOURCE Eli Lilly and Company